TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01114607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
Study: NCT03447093

Intervention type: DRUG
Intervention: Methimazole Pill
Description: Patients who developed GD received methimazole treatment
Study: NCT01114607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 ChemoCentryx: formulation A
Description: ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1605786 GSK: formulation B
Description: GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
Study: NCT03447093

Intervention type: DRUG
Intervention: Propylthiouracil Pill
Description: Patients who developed GD received propylthiouracil treatment
Study: NCT03190694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg
Description: Tablet
Study: NCT03190694

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: Tablet
Study: NCT02921009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Crosslinking using UV light of two different fluence rates
Description: The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
Study: NCT03654287

Intervention type: OTHER
Intervention: Treatment
Description: The CELS way to intervene severe sepsis and refractory shock

Intervention type: OTHER
Intervention: Treatment
Description: The CELS way to intervene severe sepsis and refractory shock

Intervention type: OTHER
Intervention: Treatment
Description: The CELS way to intervene severe sepsis and refractory shock

Intervention type: OTHER
Intervention: Treatment
Description: The CELS way to intervene severe sepsis and refractory shock
Study: NCT05697666

Intervention type: OTHER
Intervention: Modulation of the depth of the neuromuscular blockade
Description: Analysis of the respiratory mechanics at two times:~* Facial train of four = 0, indicating a deep neuromuscular blockade~* Facial train of four \> 0, indicating a intermediate to light neuromuscular blockade
Study: NCT02498574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation applied to the surface of the scalp

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: Non-invasive brain stimulation applied to the surface of the scalp

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working Memory Training
Description: Cognitively challenging game played concurrently with transcranial direct-current stimulation

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Working Memory Training
Description: Cognitively challenging game played concurrently with transcranial direct-current stimulation
Study: NCT00894478

Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging (DTI)
Description: MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan

Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging (DTI)
Description: MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan

Intervention type: PROCEDURE
Intervention: Diffusion Tensor Imaging (DTI)
Description: MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.~1. DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)~2. Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan

Intervention type: PROCEDURE
Intervention: Magnetoencephalography
Description: MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.

Intervention type: PROCEDURE
Intervention: Magnetoencephalography
Description: MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
Study: NCT02279498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liprotamase
Description: oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
Study: NCT01753674

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TA-65
Description: TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
Study: NCT00003958

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given SC
Study: NCT02279498

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porcine (pig) PERT
Description: oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
Study: NCT03294070

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Fimasartan plus amlodipine besylate
Description: Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
Study: NCT02012088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RCOMP
Description: Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RCHOP
Description: Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
Study: NCT01753674

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
Study: NCT04039776

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Cone Beam Computed Tomography (CBCT)
Description: Cone Beam Computed Tomography (CBCT), a machine that use a low dose of radiation compared to traditional CT systems, and allows the examination in supine and standing position knee . In this way, for the same patient it will be possible to calculate the bone indexes both in weight-bearing condition and in non-weight-bearing, comparing the values between them, to identify possible differences due to the influence of orthostatism.
Study: NCT00524797

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Profonycia
Study: NCT02950961

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Collaborative Care for Women Veterans
Description: This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators offered in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators trained appropriate MH providers in CALM and studied the ways in which the intervention needs to be tailored to women Veterans.
Study: NCT05976451

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: melatonin with collagen matrix
Description: (CMX) with melatonin in the esthetic zone using Modified Coronally Advanced Tunneling Technique (MCAT)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: connective tissue graft (CTG)
Description: control group connective tissue graft using Modified Coronally Advanced Tunneling Technique (MCAT)
Study: NCT00002762

Intervention type: BEHAVIORAL
Intervention: patient interviewing to obtain menstrual history

Intervention type: PROCEDURE
Intervention: blood sampling
Study: NCT02258178

Intervention type: BIOLOGICAL
Intervention: Flucelvax (cTIV)
Description: vaccine exposure in routine care (no vaccination per protocol)
Study: NCT03055988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium
Description: Fixed Dose Combination
Study: NCT00003958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02229474

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CST Intervention
Description: The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
Study: NCT01673230

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cardiac surgery for ventricular dysfunction
Description: For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
Study: NCT01314937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Single-dose 500 mg mebendazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Single-dose 500 mg mebendazole tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mebendazole
Description: Single-dose 500 mg mebendazole tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
Study: NCT01228019

Intervention type: DRUG
Intervention: Niacin (+) laropiprant
Description: Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
Study: NCT01584817

Intervention type: OTHER
Group type: OTHER
Intervention: telephone education
Description: A repeated instruction by telephone on the day before colonoscopy was conducted
Study: NCT00797589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HES
Description: 20ml/kg as prime fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringer lactate
Study: NCT03258203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Overweight Using Novel Dietary Strategies
Description: The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Overweight Using Novel Dietary Strategies
Description: The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Overweight Using Novel Dietary Strategies
Description: The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventing Overweight Using Novel Dietary Strategies
Description: The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
Study: NCT00681031

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ZOSTAVAX®
Description: One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
Study: NCT05410964

Intervention type: DEVICE
Intervention: VIO System
Description: To investigate the potential for the VIO System to display microscopic skin structure in people of different age, sex, race, and skin health
Study: NCT03252743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based internet-delivered CBT
Description: The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.~The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.~All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.~Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises.
Study: NCT02647801

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Description: Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation).
Study: NCT00473460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelox (Moxifloxacin, BAY12-8039)
Description: Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules orally once daily for 5 days every 8 weeks.
Study: NCT02756884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LoFU and aADSC
Description: Administration of low frequency ultrasound prior to administration of autologous adipose derived stem cells.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: adipose derived stem cells
Description: control arm will only received the adipose derived stem cells.
Study: NCT03504683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early TRE
Description: Eat between 8 am - 3 pm (or 7 am - 2 pm, if an early riser)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mid-day TRE
Description: Eat between 1 pm - 8 pm (or 12 pm - 7 pm, if an early riser)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Schedule
Description: Eat between 8 am - 8 pm (or 7 am - 7 pm, if an early riser)
Study: NCT01141205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFO-18
Description: 18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 1.2 ml saline intramuscularly
Study: NCT01915745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of SMS
Description: Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
Study: NCT01499446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X (fluticasone furoate) 100mcg Morning
Description: GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW685698X (fluticasone furoate) 100mcg Morning
Description: GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
Study: NCT01660529

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hTERT
Study: NCT00761033

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: music

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: music
Study: NCT04056962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment
Description: topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus ointment
Description: topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).